Debt-to-equity of Marker Therapeutics, Inc. from 30 Sep 2017 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Marker Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2017 to 30 Sep 2025.
  • Marker Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 22%, a 13% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Marker Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 22% -3.2% -13% 30 Sep 2025
Q2 2025 27% +7.5% +39% 30 Jun 2025
Q1 2025 23% +4.7% +26% 31 Mar 2025
Q4 2024 24% -8.1% -26% 31 Dec 2024
Q3 2024 25% -21% -45% 30 Sep 2024
Q2 2024 19% -43% -69% 30 Jun 2024
Q1 2024 18% -63% -78% 31 Mar 2024
Q4 2023 32% -41% -56% 31 Dec 2023
Q3 2023 46% -20% -31% 30 Sep 2023
Q2 2023 63% +8% +15% 30 Jun 2023
Q1 2023 81% +40% +97% 31 Mar 2023
Q4 2022 73% +39% +119% 31 Dec 2022
Q3 2022 66% +33% +101% 30 Sep 2022
Q2 2022 55% +19% +52% 30 Jun 2022
Q1 2022 41% +1% +2.6% 31 Mar 2022
Q4 2021 33% -7.5% -18% 31 Dec 2021
Q3 2021 33% +7.7% +30% 30 Sep 2021
Q2 2021 36% +22% +156% 30 Jun 2021
Q1 2021 40% +33% +474% 31 Mar 2021
Q4 2020 41% +34% +534% 31 Dec 2020
Q3 2020 25% +19% +308% 30 Sep 2020
Q2 2020 14% +5.9% +73% 30 Jun 2020
Q1 2020 7% -4.4% -39% 31 Mar 2020
Q4 2019 6.4% -13% -67% 31 Dec 2019
Q3 2019 6.2% -118% -95% 30 Sep 2019
Q2 2019 8.1% -57% -88% 30 Jun 2019
Q1 2019 11% -27% -70% 31 Mar 2019
Q4 2018 19% -11% -37% 31 Dec 2018
Q3 2018 124% +96% +337% 30 Sep 2018
Q2 2018 65% 30 Jun 2018
Q1 2018 38% 31 Mar 2018
Q4 2017 31% 31 Dec 2017
Q3 2017 28% 30 Sep 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.